CN116509878B - 防止卵巢储备功能下降的药物组合物及其应用 - Google Patents
防止卵巢储备功能下降的药物组合物及其应用 Download PDFInfo
- Publication number
- CN116509878B CN116509878B CN202310714564.0A CN202310714564A CN116509878B CN 116509878 B CN116509878 B CN 116509878B CN 202310714564 A CN202310714564 A CN 202310714564A CN 116509878 B CN116509878 B CN 116509878B
- Authority
- CN
- China
- Prior art keywords
- agents
- pharmaceutical composition
- ovarian reserve
- cryptotanshinone
- coenzyme
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000002611 ovarian Effects 0.000 title claims abstract description 30
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 22
- GVKKJJOMQCNPGB-JTQLQIEISA-N Cryptotanshinone Chemical compound O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1[C@@H](C)CO2 GVKKJJOMQCNPGB-JTQLQIEISA-N 0.000 claims abstract description 19
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 19
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims abstract description 18
- 235000017471 coenzyme Q10 Nutrition 0.000 claims abstract description 18
- 229940110767 coenzyme Q10 Drugs 0.000 claims abstract description 18
- GVKKJJOMQCNPGB-UHFFFAOYSA-N Cryptotanshinone Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)CO2 GVKKJJOMQCNPGB-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims description 9
- 230000007423 decrease Effects 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 5
- -1 glidants Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000002250 absorbent Substances 0.000 claims description 2
- 230000002745 absorbent Effects 0.000 claims description 2
- 239000003463 adsorbent Substances 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 235000006708 antioxidants Nutrition 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- 239000003906 humectant Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000004014 plasticizer Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 239000003380 propellant Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000000375 suspending agent Substances 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 239000006172 buffering agent Substances 0.000 claims 1
- 239000003205 fragrance Substances 0.000 claims 1
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- 239000008181 tonicity modifier Substances 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 8
- 230000009467 reduction Effects 0.000 abstract description 5
- 230000002265 prevention Effects 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 241000700159 Rattus Species 0.000 description 13
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 8
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 8
- 230000035558 fertility Effects 0.000 description 7
- 229940028334 follicle stimulating hormone Drugs 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 210000001672 ovary Anatomy 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 102000009151 Luteinizing Hormone Human genes 0.000 description 6
- 108010073521 Luteinizing Hormone Proteins 0.000 description 6
- 229940040129 luteinizing hormone Drugs 0.000 description 5
- 230000037396 body weight Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 206010036601 premature menopause Diseases 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000002500 Primary Ovarian Insufficiency Diseases 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 230000006578 abscission Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000012173 estrus Effects 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 239000003163 gonadal steroid hormone Substances 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000002262 irrigation Effects 0.000 description 2
- 238000003973 irrigation Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 208000017942 premature ovarian failure 1 Diseases 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000005641 Adenomyosis Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000028685 Asherman syndrome Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- 206010061619 Deformity Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 201000001389 adhesions of uterus Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229940090047 auto-injector Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 201000009274 endometriosis of uterus Diseases 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 231100000502 fertility decrease Toxicity 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000006589 gland dysfunction Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000009933 reproductive health Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明涉及用于防止卵巢储备功能下降的药物组合物及其应用。所述药物组合物包含辅酶Q10和隐丹参酮，二者在防止卵巢储备功能下降产生明显的协同增效作用，可以大幅提高预防和治疗卵巢储备功能下降的效果，因此能够大大减少药物用量，从而具有更好的预防治疗效果和安全性。
Description
技术领域
本发明涉及医药领域，具体来说，本发明涉及一种防止卵巢储备功能下降的药物组合物，本发明还涉及所述药物组合物的应用。
背景技术
卵巢储备功能(Ovarian Reservation,OR)是指卵巢皮质区内储存卵子数量和质量的潜能，与女性生育能力密切相关。当卵巢内存留的原始卵泡过早耗尽、卵泡生长障碍及闭锁加速导致卵泡数量减少或卵母细胞质量下降，近而导致生育潜能下降和内分泌功能紊乱时，称之为卵巢储备功能下降(DOR)。DOR临床主要表现为月经稀发、经量减少，甚至闭经、不孕等一系列围绝经期的临床症状，如不尽早干预将逐渐演变成卵巢早衰(prematureovarian failure，POF)，严重影响患者的生殖健康和生活质量。因此，对于DOR患者亟需进行早期干预与预防，保护卵巢功能，提高患者的生活质量和生育功能。
DOR的发生除卵巢功能的生理性衰退外，还与遗传学因素、医源性因素、感染因素、自身免疫性疾病、心理社会因素及不良生活习惯等有关。上述病因可导致基因组DNA突变和表观修饰的改变、端粒缩短和端粒酶活性下降、卵巢微环境的改变(包括卵巢免疫功能的改变、卵巢间质的改变及细胞因子的改变等)、氧化应激损伤、卵泡池的耗竭、卵巢血供受阻等，从而引起DOR；此外，近年来有研究发现，线粒体遗传的异常(包括线粒体数量变化、线粒体DNA片段缺失、突变等)亦可加速卵母细胞的凋亡并导致DOR的发生。
DOR的纳入标准包括：①20岁≤年龄≤40岁；②自然周期双侧卵巢窦卵泡数(AFC)≤5个；③卵泡刺激素(FSH)≥l0mIU/mL或抗苗勒管激素(AMH)≤1.1mIU/mL。排除标准：辅助生殖技术助孕周期数>3、宫腔粘连病史、子宫畸形、子宫内膜异位症、子宫腺肌病、甲状腺和肾上腺功能异常等。
DOR的西医治疗分为非生育期和生育期，非生育期患者主要是补充性激素，改善临床症状，保存患者生育能力；有生育需求的患者则积极试孕或直接应用辅助生殖技术进行助孕治疗，在治疗周期中应用预处理药物如脱氢表雄酮(DHEA)和生长激素(GH)，以及控制性超促排卵(COH)。中医治疗主要是平衡气血阴阳，调理脏腑冲任，补虚泻实。但是，目前中西医治疗DOR的方法各有利弊，西医治疗见效快，但价格昂贵、不良反应和禁忌证较多；中医治疗强调整体观，以补肾为治疗大法，但存在治疗时间长，患者治疗依从性差的缺点。因此，有必要提供更为有效、安全的DOR治疗方法。
发明内容
针对现有技术存在的上述问题，本发明提供了一种用于防止卵巢储备功能下降的药物组合物，其具有改善的防止卵巢储备功能下降的作用。
在本发明的一个方面，本发明提供了一种药物组合物，包含辅酶Q10和隐丹参酮，辅酶Q10和隐丹参酮的重量比为(1-10)：(10-1)。
在一个实施方案中，辅酶Q10和隐丹参酮的重量比为(1-2)：(3-8)。
在一个实施方案中，辅酶Q10和隐丹参酮的重量比为2：4-6，优选为2：5。
在一个实施方案中，所述药物组合物还包含一种或更多种药学上可接受的载体。
进一步，上述药物组合物中，所述其他药学上可接受的载体选自赋形剂、抛射剂、增溶剂、助溶剂、乳化剂、着色剂、黏合剂、崩解剂、填充剂、润滑剂、润湿剂、渗透压调节剂、稳定剂、助流剂、矫味剂、防腐剂、助悬剂、包衣材料、芳香剂、抗黏合剂、整合剂、渗透促进剂、pH值调节剂、缓冲剂、增塑剂、表面活性剂、发泡剂、消泡剂、增稠剂、包合剂、保湿剂、吸收剂、稀释剂、絮凝剂与反絮凝剂、抗氧剂、吸附剂、助滤剂、释放阻滞剂中的至少一种。
进一步，上述药物组合物中，作为上述药学上可接受的载体，选自例如水、乳糖、右旋糖、果糖、蔗糖、山梨糖醇、甘露醇、聚乙二醇、丙二醇、淀粉、橡胶、明胶、海藻酸盐、硅酸钙、磷酸钙、纤维素、羟丙基甲基纤维素、羧甲基淀粉钠、糖水、甲基纤维素、聚乙烯基吡咯烷酮、对羟基苯山梨酸烷基酯、滑石、硬脂酸镁、硬脂酸、十二烷基硫酸钠、甘油、芝麻油、橄榄油、大豆油中的至少一种。
所述药物组合物以单位剂型呈现，所述单位剂型为诸如片剂、丸剂、胶囊剂、散剂、颗粒剂、混悬剂、口服液体剂、气雾剂或液体喷雾剂、滴剂、安瓿、自我注射器装置或栓剂；用于口腔的胃肠外、鼻内、舌下或直肠给药或用于吸入或喷射给药的剂型。优选所述药物剂型为口服制剂，更优选是片剂、丸剂、胶囊剂、颗粒剂、混悬剂、散剂、口服液体剂。
本发明的药物组合物可以采用本领域众所周知的方法制造，如常规的混合法、溶解法、制粒法、制糖衣药丸法、磨细法、乳化法、冷冻干燥法等等。药学上本发明药物组合物中活性成分的含量应在整个组合物的0.05重量％至90重量％、优选0.1重量％至50重量％范围内。
对于成人患者，本发明化合物能够以口服或非口服的方式将作为1次的给予量的0.001～500mg、1天1次或分为数次来给予。应予说明，该给予量可根据治疗对象的疾病的种类、患者的年龄、体重、症状等适当增减。
本发明另一方面提供了所述药物组合物在制备药物中的应用，所述药物用于：1)预防和/或治疗防止卵巢储备功能下降；或者2)提高卵巢功能。
有益效果
本发明提供了一种用于防止卵巢储备功能下降的药物组合物，所述药物组合物包含辅酶Q10和隐丹参酮。辅酶Q10和隐丹参酮均能在一定程度上提高卵巢功能，本发明发现辅酶Q10和隐丹参酮在防止卵巢储备下降、提高卵巢功能上具有协同增效作用，可以大幅提高预防和治疗卵巢储备功能下降的效果，因此能够大大减少药物用量，从而具有更好的预防治疗效果和安全性。
具体实施方式
在下文中更详细地描述了本发明以有助于对本发明的理解。
下面实施例中的实验方法，如无特殊说明，均为常规方法。实施例中未注明具体技术或条件者，按照本领域内的文献所描述的技术或条件，或者按照产品说明书进行。
实施例1：本发明药物组合物对DOR的效果
1实验方法
取SPF雌性SD大鼠(年龄12周；无出生；体重200±15g)适应性喂养一周后，通过大鼠阴道脱落细胞美兰染色涂片于显微镜下观察大鼠的动情周期，取动情周期正常的大鼠进行实验。除正常对照组外，其余大鼠采用一次性腹腔注射环磷酰胺75mg/kg制备DOR大鼠模型，造模第二天开始于每天上午8点，行大鼠阴道脱落细胞美兰染色涂片，若涂片显示周期延长、紊乱提示造模成功。实验中共有38只大鼠造模成功，从中随机选取32只并进行随机分组，按照下列方案每天灌胃给药，连续给药28d。
表1：动物分组及给药信息表(n＝8)
| 分组 | 每日给药方案 |
| 正常组 | 灌胃生理盐水 |
| 模型组 | 灌胃生理盐水 |
| 辅酶Q10组 | 20mg·kg-1·d-1 |
| 隐丹参酮组 | 50mg·kg-1·d-1 |
| 辅酶Q10+隐丹参酮组 | 辅酶Q1020mg·kg-1·d-1+隐丹参酮50mg·kg-1·d-1 |
2结果采集
第28天给药结束后，乙醚吸入麻醉大鼠，心脏取血，收集血清。用ELISA法检测各组大鼠血清AMH(抗穆勒氏激素)、E2(雌二醇)、FSH(卵泡刺激素)和LH(黄体生成激素)的水平，根据试剂盒(武汉华美公司)说明书进行操作。AMH、E2、FSH、LH水平是反映卵巢储备功能力的指标，AMH、E2水平降低，FSH、LH水平升高与卵巢储备功能降低息息相关。用全波长酶标仪于波长450nm处检测光密度(OD)值，绘制标准化曲线，计算AMH、E2、FSH、LH浓度。称重后处死大鼠，分离大鼠的卵巢、子宫并称重，计算单侧卵巢指数(单侧卵巢重量mg/大鼠体重g)、子宫指数(子宫重量mg/大鼠体重g)。统计学分析采用SPSS26.0软件行统计学分析，数据用均值±标准差表示，同一列数值上不同字母表示存在显著性差异(P<0.05)。结果示于以下表2和表3中：
表2：各组大鼠体重、卵巢指数、子宫指数的比较(n＝8)
表3：各组大鼠血清抗苗勒氏管激素和性激素水平的比较(n＝8)
表2和表3的结果显示，模型组大鼠的体重、卵巢指数显著降低，E2和AMH水平降低，FSH和LH水平增加，差异均有统计学意义，表明建模成功。所述用量的辅酶Q10和隐丹参酮在防止DOR上效果一般，而辅酶Q10和隐丹参酮的组合相比于辅酶Q10和隐丹参酮单独使用，能够更为显著地缓解体重、卵巢指数降低的情况，并且可以显著改善AMH和E2水平降低、FSH和LH水平增加的情况，差异均有统计学意义。这表明辅酶Q10和隐丹参酮在防止DOR上具有协同增效的作用。
实施例2：片剂组合物
制备方法：
第一步辅酶Q10和隐丹参酮过100目筛，其他辅料过80目筛；
第二步称取处方量的辅酶Q10，与处方量的十二烷基硫酸钠、羧甲基淀粉钠混合均匀，用45％乙醇湿润制软材；
第三步加入处方量的乳糖、羟丙基甲基纤维素，混匀，用45％乙醇湿润制软材，整粒；过40目筛；
第四步加入处方量的硬脂酸镁，压片。每片含有20mg的辅酶Q10，50mg的隐丹参酮。
以上所述仅是本发明的优选实施方式，应当指出，对于本技术领域的普通技术人员，在不脱离本发明方法的前提下，还可以做出若干改进和补充，这些改进和补充也应视为本发明的保护范围。
Claims (5)
1.一种药物组合物在制备药物中的应用，所述药物组合物包含辅酶Q10和隐丹参酮，辅酶Q10和隐丹参酮的重量比为2：4-6，所述药物用于：1)预防和/或治疗防止卵巢储备功能下降；或者2)提高卵巢储备功能。
2.根据权利要求1所述的应用，其特征在于，辅酶Q10和隐丹参酮的重量比为2：5。
3.根据权利要求1所述的应用，其特征在于，所述药物组合物还包含一种或更多种药学上可接受的载体。
4.根据权利要求3所述的应用，其特征在于，所述药学上可接受的载体选自赋形剂、抛射剂、增溶剂、助溶剂、乳化剂、着色剂、黏合剂、崩解剂、填充剂、润滑剂、润湿剂、渗透压调节剂、稳定剂、助流剂、矫味剂、防腐剂、助悬剂、包衣材料、芳香剂、抗黏合剂、整合剂、渗透促进剂、pH值调节剂、缓冲剂、增塑剂、表面活性剂、增稠剂、包合剂、保湿剂、吸收剂、稀释剂、絮凝剂与反絮凝剂、抗氧剂、吸附剂、助滤剂、释放阻滞剂中的至少一种。
5.根据权利要求1所述的应用，其特征在于，所述药物组合物选自片剂、丸剂、胶囊剂、散剂、颗粒剂、混悬剂、口服液体剂、气雾剂或液体喷雾剂、滴剂、或栓剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310714564.0A CN116509878B (zh) | 2023-06-16 | 2023-06-16 | 防止卵巢储备功能下降的药物组合物及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310714564.0A CN116509878B (zh) | 2023-06-16 | 2023-06-16 | 防止卵巢储备功能下降的药物组合物及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116509878A CN116509878A (zh) | 2023-08-01 |
| CN116509878B true CN116509878B (zh) | 2024-04-30 |
Family
ID=87401370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310714564.0A Active CN116509878B (zh) | 2023-06-16 | 2023-06-16 | 防止卵巢储备功能下降的药物组合物及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116509878B (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101810862A (zh) * | 2009-02-20 | 2010-08-25 | 北京大学 | 丹参酮ⅱa口服聚合物胶束组合物 |
| CN105878374A (zh) * | 2016-04-12 | 2016-08-24 | 程凤森 | 一种含丹参脂溶性成分和辅酶q10的组合物及其制备方法及采用该组合物的药物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007517025A (ja) * | 2003-12-30 | 2007-06-28 | エムディー バイオアルファ カンパニー リミテッド | 代謝活性を上昇させるタンシノン誘導体を用いる、肥満およびメタボリックシンドロームの治療 |
| US20060153926A1 (en) * | 2005-01-10 | 2006-07-13 | Bascom Charles C | Compositions, products and methods for controlling weight in a mammal |
| AU2009234283B2 (en) * | 2008-04-11 | 2015-04-02 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Diterpene glycosides as natural solubilizers |
| CN102481372B (zh) * | 2009-06-24 | 2016-05-11 | 路易斯安那州州立大学及农业机械学院管理委员会 | 作为增溶剂的萜类糖苷及其组合 |
-
2023
- 2023-06-16 CN CN202310714564.0A patent/CN116509878B/zh active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101810862A (zh) * | 2009-02-20 | 2010-08-25 | 北京大学 | 丹参酮ⅱa口服聚合物胶束组合物 |
| CN105878374A (zh) * | 2016-04-12 | 2016-08-24 | 程凤森 | 一种含丹参脂溶性成分和辅酶q10的组合物及其制备方法及采用该组合物的药物 |
Non-Patent Citations (3)
| Title |
|---|
| Cryptotanshinone decreases granulosa cell apoptosis and restores ovarian function in mice with premature ovarian failure;Jianzhen Huang et al.;《Gen. Physiol. Biophys.》;20201231;第39卷;摘要部分 * |
| 王云铭治疗卵巢储备功能下降所致不孕的经验;靳凡钰等;中国医药导报;20231130;第11卷(第31期);第144页左栏部分 * |
| 辅酶 Q10 对卵巢储备功能下降患者的防治作用;赵梦璐等;《医药导报》;20200131;39(1);摘要部分；第75页结束语部分 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116509878A (zh) | 2023-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200831107A (en) | Methods of hormonal treatment utilizing ascending-dose extended cycle regimens | |
| JP2590358B2 (ja) | 子宮内膜症治療用の子宮内又は膣内投与製剤 | |
| CN108025014B (zh) | 用于过重女性患者的基于屈螺酮的避孕药 | |
| SG187529A1 (en) | Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof | |
| Blackburn et al. | Morphologic changes in the developing rat placenta following prednisolone administration | |
| CN1211087C (zh) | 用于适应需要的女性生育节制的竞争性黄体酮拮抗剂 | |
| KR20000048981A (ko) | 에스트로겐 화합물 및 프로게스테론 화합물로 이루어진 호르몬 조성물 | |
| CN116509878B (zh) | 防止卵巢储备功能下降的药物组合物及其应用 | |
| Kajanoja et al. | Rupture of the cervix in prostaglandin abortions | |
| CN116370444B (zh) | 一种辅酶q10用于制备预防及治疗主动脉夹层药物的用途 | |
| EISENSTEIN et al. | Occurrence of pregnancy in Cushing's syndrome | |
| JP4418102B2 (ja) | ジエノゲストを有効成分とする子宮筋腫治療剤 | |
| CN113876767B (zh) | 改善多囊卵巢综合征患者月经周期的制剂 | |
| CN111281867B (zh) | 一种治疗多囊卵巢综合征的药物及其制备方法 | |
| Armatage et al. | A randomized trial of 2 regimens for the administration of vaginal prostaglandins (gemeprost) for the induction of midtrimester abortion | |
| US7488723B2 (en) | Use of non-feminizing estrogens as treatment for retinal vascular diseases | |
| WO2010007629A1 (en) | A kit comprising anti-emetic and oral contraceptive | |
| EP3244885B1 (en) | Lipoic acid for treating or preventing threatened miscarriage or preterm delivery | |
| Yazdani et al. | Investigating the comparative effect of combined regimens of letrozole with misoprostol alone for first trimester medical abortion | |
| EP2027855A1 (de) | Verwendung von Gestagenen in Kombination mit (6S)5-Methyltetrahydrofolat zur Therapie der Endometriose mit gleichzeitiger Verminderung von Therapie-Nebenwirkungen sowie der Verminderung des Risikos angeborener Fehlbildungen bei Eintritt einer Gravidität | |
| WO2023152682A1 (en) | Contraceptive methods with scheduled bleeding effects | |
| CN101068552A (zh) | 利用提高剂量长周期给药方案进行激素治疗的方法 | |
| Tang et al. | Pharmacology of Prostaglandins | |
| CN111035763A (zh) | 一种治疗妇女更年期综合症的药物组合物 | |
| Obasi et al. | Histomorphometric Studies of Oral Contraceptives on the Ovaries of Adult Female Wistar Rats (Rattus Norvegicus) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |